Payment overview · 2025
General Payments
$1,464.53
80 reported records · 14 companies
Healthcare provider profile · identity verified
Valeri I Kazakov, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BRONX, NY · NPI 1487633772
Verified facts
What the public records show
CMS Open Payments records show Valeri I Kazakov, MD received $1,464.53 in general payments during 2025 across 80 reported records.
ABBVIE INC. accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Linzess, Mounjaro, Nurtec Odt, Ozempic, Qulipta, Rybelsus, Trelegy Ellipta, Ubrelvy, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 261 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Viibryd by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ztlido by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $266.17 | 18.2% | 16 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $205.40 | 14.0% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $174.94 | 11.9% | 8 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $170.70 | 11.7% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $133.85 | 9.1% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $83.72 | 5.7% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $79.56 | 5.4% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $72.37 | 4.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $68.53 | 4.7% | 3 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $62.58 | 4.3% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $57.47 | 3.9% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.60 | 3.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.01 | 1.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.63 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,449.90 | 79 |
| Education | $14.63 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $240.82 | 12 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $205.40 | 20 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $186.01 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $174.94 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $174.94 | 8 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $170.70 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $109.80 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $83.72 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $79.56 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $79.56 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $68.53 | 3 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $62.58 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $57.47 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $54.88 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.60 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.60 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $49.91 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $37.09 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $28.84 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $7.03 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $7.03 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 118 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 228 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 261 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 130 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 73 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 181 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 144 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 32 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
118 | 28 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
261 | 54 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
213 | 35 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
32 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIIBRYD open payments reported associated product |
CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050 |
Viibryd · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
105 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
117 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
144 | 50 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
130 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
76 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
181 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
228 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
73 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
49 | 26 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 648 | 142 |
| Metoprolol Succinate | Metoprolol Succinate | 598 | 123 |
| Zolpidem Tartrate | Zolpidem Tartrate | 565 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 527 | 119 |
| Omeprazole | Omeprazole | 499 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 489 | 118 |
| Tamsulosin Hcl | Tamsulosin Hcl | 410 | 100 |
| Celecoxib | Celecoxib | 408 | 151 |
| Atenolol | Atenolol | 386 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 380 | 72 |
| Losartan Potassium | Losartan Potassium | 374 | 75 |
| Levothyroxine Sodium | Levothyroxine Sodium | 372 | 67 |
| Metformin Hcl | Metformin Hcl | 365 | 82 |
| Diclofenac Sodium | Diclofenac Sodium | 348 | 92 |
| Metformin Er Gastric | Metformin Hcl | 332 | 51 |
| Nifedipine Er | Nifedipine | 304 | 51 |
| Furosemide | Furosemide | 268 | 72 |
| Lisinopril | Lisinopril | 263 | 46 |
| Linzess | Linaclotide | 261 | 54 |
| Gabapentin | Gabapentin | 254 | 65 |
| Simvastatin | Simvastatin | 253 | 53 |
| Famotidine | Famotidine | 252 | 74 |
| Eliquis | Apixaban | 228 | 46 |
| Memantine Hcl | Memantine Hcl | 216 | 40 |
| Synthroid | Levothyroxine Sodium | 213 | 35 |
| Donepezil Hcl | Donepezil Hcl | 210 | 30 |
| Meclizine Hcl | Meclizine Hcl | 200 | 70 |
| Azithromycin | Azithromycin | 196 | 148 |
| Metoprolol Tartrate | Metoprolol Tartrate | 192 | 32 |
| Ozempic | Semaglutide | 181 | 37 |
| Ranolazine Er | Ranolazine | 180 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 32 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 178 | 46 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 176 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 175 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 165 | 34 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 163 | 35 |
| Clonazepam | Clonazepam | 161 | 48 |
| Potassium Chloride | Potassium Chloride | 159 | 39 |
| Allopurinol | Allopurinol | 158 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 158 | 44 |
| Naproxen | Naproxen | 151 | 53 |
| Ibuprofen | Ibuprofen | 148 | 105 |
| Dexlansoprazole Dr | Dexlansoprazole | 147 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 144 | 50 |
| Azelastine Hcl | Azelastine Hcl | 140 | 91 |
| Januvia | Sitagliptin Phosphate | 136 | 25 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 135 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 135 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 27 |
| Mounjaro | Tirzepatide | 130 | 28 |
| Lidocaine | Lidocaine | 128 | 40 |
| Creon | Lipase/Protease/Amylase | 118 | 28 |
| Nexium | Esomeprazole Magnesium | 117 | 20 |
| Montelukast Sodium | Montelukast Sodium | 115 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 46 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 106 | 56 |
| Prednisone | Prednisone | 106 | 68 |
| Myrbetriq | Mirabegron | 105 | 25 |
| Nitroglycerin Patch | Nitroglycerin | 105 | 25 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 104 | 32 |
| Carvedilol | Carvedilol | 104 | 25 |
| Lactulose | Lactulose | 104 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 101 | 27 |
| Crestor | Rosuvastatin Calcium | 99 | 13 |
| Cyclosporine | Cyclosporine | 98 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 98 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 98 | 20 |
| Glimepiride | Glimepiride | 97 | 25 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 93 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 93 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 89 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 88 | 32 |
| Dexilant | Dexlansoprazole | 88 | 16 |
| Icosapent Ethyl | Icosapent Ethyl | 81 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 80 | 54 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 77 | 16 |
| Mirtazapine | Mirtazapine | 76 | 17 |
| Tribenzor | Olmesartan/Amlodipin/Hcthiazid | 76 | 13 |
| Trulicity | Dulaglutide | 76 | suppressed |
| Meloxicam | Meloxicam | 74 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 73 | 29 |
| Nurtec Odt | Rimegepant Sulfate | 73 | 20 |
| Ammonium Lactate | Ammonium Lactate | 72 | 28 |
| Pregabalin | Pregabalin | 72 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 72 | 29 |
| Ambien | Zolpidem Tartrate | 71 | suppressed |
| Glipizide | Glipizide | 69 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 69 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 65 | 40 |
| Diclofenac Epolamine | Diclofenac Epolamine | 63 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 63 | 42 |
| Enalapril Maleate | Enalapril Maleate | 62 | 13 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 61 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 58 | suppressed |
| Ezetimibe | Ezetimibe | 57 | 12 |
| Finasteride | Finasteride | 56 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 17 |
| Latanoprost | Latanoprost | 56 | 15 |
| Torsemide | Torsemide | 56 | 13 |
| Clonidine Hcl | Clonidine Hcl | 55 | 15 |
| Entresto | Sacubitril/Valsartan | 55 | 12 |
| Mesalamine | Mesalamine | 53 | suppressed |
| Procto-Med Hc | Hydrocortisone | 53 | 13 |
| Propranolol Hcl | Propranolol Hcl | 53 | 16 |
| Alprazolam | Alprazolam | 52 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | suppressed |
| Jardiance | Empagliflozin | 52 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 52 | 16 |
| Silver Sulfadiazine | Silver Sulfadiazine | 52 | 24 |
| Nitroglycerin | Nitroglycerin | 50 | 23 |
| Sertraline Hcl | Sertraline Hcl | 50 | suppressed |
| Kerendia | Finerenone | 49 | suppressed |
| Ztlido | Lidocaine | 49 | 26 |
| Lorazepam | Lorazepam | 48 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 48 | suppressed |
| Risperidone | Risperidone | 48 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 48 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | suppressed |
| Ketoconazole | Ketoconazole | 46 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 46 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 45 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 45 | 21 |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 44 | suppressed |
| Dutasteride | Dutasteride | 44 | suppressed |
| Mupirocin | Mupirocin | 44 | 20 |
| Proctozone-Hc | Hydrocortisone | 44 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 43 | 13 |
| Cilostazol | Cilostazol | 43 | suppressed |
| Levofloxacin | Levofloxacin | 43 | 31 |
| Mometasone Furoate | Mometasone Furoate | 43 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 43 | 18 |
| Clotrimazole | Clotrimazole | 42 | 13 |
| Memantine Hcl Er | Memantine Hcl | 42 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Hydrocortisone | Hydrocortisone | 41 | 16 |
| Telmisartan | Telmisartan | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 22 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Colchicine | Colchicine | 38 | 12 |
| Diovan | Valsartan | 38 | suppressed |
| Valsartan | Valsartan | 38 | suppressed |
| Azor | Amlodipine Bes/Olmesartan Med | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Bystolic | Nebivolol Hcl | 36 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 36 | 11 |
| Livalo | Pitavastatin Calcium | 35 | suppressed |
| Qulipta | Atogepant | 35 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 34 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 28 |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 32 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Ubrelvy | Ubrogepant | 32 | 13 |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | 20 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | 23 |
| Rivastigmine | Rivastigmine | 30 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 30 | 27 |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 28 | suppressed |
| Alogliptin | Alogliptin Benzoate | 28 | suppressed |
| Calcitriol | Calcitriol | 28 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Trulance | Plecanatide | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 27 | 15 |
| Glipizide Er | Glipizide | 27 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 27 | 13 |
| Risedronate Sodium | Risedronate Sodium | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Eplerenone | Eplerenone | 26 | suppressed |
| Loperamide | Loperamide Hcl | 26 | 12 |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Temazepam | Temazepam | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 23 | 15 |
| Amoxicillin | Amoxicillin | 22 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Cephalexin | Cephalexin | 22 | 20 |
| Clonidine | Clonidine | 22 | suppressed |
| Febuxostat | Febuxostat | 22 | suppressed |
| Restasis | Cyclosporine | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | 19 |
| Fluconazole | Fluconazole | 21 | 13 |
| Micardis Hct | Telmisartan/Hydrochlorothiazid | 21 | suppressed |
| Plavix | Clopidogrel Bisulfate | 21 | suppressed |
| Zaleplon | Zaleplon | 21 | suppressed |
| Actonel | Risedronate Sodium | 20 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | 13 |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Nystop | Nystatin | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 16 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fluocinonide | Fluocinonide | 15 | suppressed |
| Hyzaar | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Tobradex | Tobramycin/Dexamethasone | 15 | suppressed |
| Acarbose | Acarbose | 14 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 14 | 13 |
| Humulin N | Insulin Nph Human Isophane | 14 | suppressed |
| Lovaza | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Fosamax | Alendronate Sodium | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Micardis | Telmisartan | 13 | suppressed |
| Prevacid | Lansoprazole | 13 | suppressed |
| Tavaborole | Tavaborole | 13 | suppressed |
| Benicar | Olmesartan Medoxomil | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 12 | suppressed |
| Flomax | Tamsulosin Hcl | 12 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Restasis Multidose | Cyclosporine | 12 | suppressed |
| Ssd | Silver Sulfadiazine | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Lamotrigine Er | Lamotrigine | 11 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 11 | suppressed |
| Mitigare | Colchicine | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Pitavastatin Calcium | Pitavastatin Calcium | 11 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 11 | suppressed |
| Viibryd | Vilazodone Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,464.53 · 80 records | ABBVIE INC. | BREZTRI, CREON, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VYEPTI, Veozah, XIFAXAN, ZAVZPRET, ZEPBOUND, ZTLido | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error